09926 AKESO
- 67.550
- -2.850-4.05%
AKESO News
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2024
AKESO: Next Day Disclosure Return
AKESO: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE
AKESO: PLACING OF NEW SHARES UNDER GENERAL MANDATE
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2024
AKESO: VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE NEW DRUG APPLICATION OF (EBRONUCIMAB, PCSK9)
AKESO: VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE SNDA OF (CADONILIMAB, PD-1/CTLA-4)IN COMBINATION WITH CHEMOTHERAPYAS A FIRST-LINE TREATMENT FOR GASTRIC CANCER
AKESO: 2024 INTERIM REPORT
AKESO: VOLUNTARY ANNOUNCEMENT - PFS HR 0.51, MPFS 11.14 MONTHSIVONESCIMAB MONOTHERAPY VS PEMBROLIZUMABAS 1L TREATMENT OF PD-L1 POSITIVE NSCLC(AK112-303/HARMORNI-2) PHASE III RESULTSPUBLISHED AT 2024 WCLC
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2024
AKESO: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
AKESO: DATE OF BOARD MEETING
AKESO: VOLUNTARY ANNOUNCEMENT - AK112-303/HARMONI-2 WAS ACCEPTED AS LBA OF 2024 WCLCPRESIDENTIAL SYMPOSIUM ORAL PRESENTATION
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2024
AKESO: VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATIONFOR IVONESCIMAB (PD-1/VEGF) MONOTHERAPY AS FIRST-LINETREATMENT FOR NSCLC WITH POSITIVE PD-L1 EXPRESSION
AKESO: APPOINTMENT OF CHIEF FINANCIAL OFFICER
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2024
AKESO: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
AKESO: CHANGE OF DIRECTORS
AKESO: POLL RESULTS OF THE ANNUAL GENERAL MEETINGHELD ON SUNDAY, JUNE 30, 2024
Analysis
Price Target
No Data
No Data